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Raloxifene was approved for chemoprevention against breast cancer among high-risk women in addition to tamoxifen by the US
Food and Drug Administration. This study aims to evaluate cost-effectiveness of these agents under Japan’s health system. A cost-
effectiveness analysis with Markov model consisting of eight health states such as healthy, invasive breast cancer, and endometrial
cancer is carried out. The model incorporated the findings of National Surgical Adjuvant Breast and Bowel Project P-1 and P-2 trial,
and key costs obtained from health insurance claim reviews. Favourable results, that is cost saving or cost-effective, are found by both
tamoxifen and raloxifene for the introduction of chemoprevention among extremely high-risk women such as having a history of
atypical hyperplasia, a history of lobular carcinoma in situ or a 5-year predicted breast cancer risk of X5.01% starting at younger age,
whereas unfavourable results, that is ‘cost more and gain less’ or cost-ineffective, are found for women with a 5-year predicted breast
cancer risk of p5.00%. Therapeutic policy switch from tamoxifen to raloxifene among postmenopausal women are implied cost-
effective. Findings suggest that introduction of chemoprevention targeting extremely high-risk women in Japan can be justifiable as an
efficient use of finite health-care resources, possibly contributing to cost containment.
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Several clinical trials have demonstrated the effectiveness of
prophylactic administration of selective oestrogen receptor modu-
lators (SERMs) such as tamoxifen (Fisher et al, 2005; Cuzick et al,
2007; Powles et al, 2007; Veronesi et al, 2007b) and raloxifene
(Cauley et al, 2001; Martino et al, 2004; Vogel et al, 2006) in
reducing incidence of breast cancer among women at high risk of
developing the disease. Tamoxifen was approved for prophylaxis
by the US Food and Drug Administration in 1998, and raloxifene
was also approved for postmenopausal women in 2007.
Tamoxifen reduces the risk of breast cancer whereas increasing
the risk of adverse events such as endometrial cancer and
pulmonary embolism. Raloxifene is a second-generation SERM
usually used for osteoporosis treatment, and it reduces the risk of
invasive breast cancer with a lower risk of known adverse events
associated with SERMs, compared to tamoxifen. This is because
raloxifene does not induce the unwanted stimulation of endo-
metrium (Delmas et al, 1997). Therefore, raloxifene is considered
to have a better clinical property as prophylactic agent, although it
is inferior to tamoxifen in preventing noninvasive breast cancer.
More women at high risk of developing breast cancer are expected
to take raloxifene as their breast cancer prevention drug in the
United States (Bevers, 2007).
However, both of these agents have been neither approved nor
made available for its use as breast cancer prevention in Japan,
although experts have shown their expectations (Iwata and Saeki,
2006). It is said that there are five hurdles to overcome in
addressing intervention in the diffusion process of new drug:
quality, safety, efficacy, cost-effectiveness, and affordability (True-
man et al, 2001). This paper aims to present evidence to the fourth
hurdle, cost-effectiveness of both agents, under Japan’s health
system. Although cost-effectiveness of prophylactic use of
tamoxifen has been reported from the USA (Noe et al, 1999;
Grann et al, 2000; Smith and Hillner, 2000; Hershman et al, 2002;
Melnikow et al, 2006) and Australia (Eckermann et al, 2003), that
of raloxifene has not been published to date except as a part of
economic evaluation of osteoporosis management (Armstrong
et al, 2001; Kanis et al, 2005). This paper also simulates a
therapeutic policy switch from tamoxifen to raloxifene among
postmenopausal women to illustrate the relative value of
raloxifene. Consequently, it should have implications to the
developed countries where chemoprevention with tamoxifen is
already in practise.
METHODS
We conduct a cost-effectiveness analysis with Markov modelling
based on the findings of the National Surgical Adjuvant Breast and
Bowel Project (NSABP) P-1 trial (Fisher et al, 2005), the NSABP
P-2 trial (Vogel et al, 2006), and the literature on costing under
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perspective. Although longer follow-up results for tamoxifen are
reported from the first International Breast Cancer Intervention
Study (IBIS-I; Cuzick et al, 2007) and the Royal Marsden trial
(Powles et al, 2007), NSABP P-1 trial with a shorter follow-up
period is chosen as clinical evidence for our modelling to make
clear comparisons with NSABP P-2 trial of raloxifene. The long-
term outcomes for tamoxifen (Veronesi et al, 2007a) are
considered in our sensitivity analyses. We use TreeAge Pro 2008
(TreeAge Software Inc.) for our economic modelling.
High-risk women
We model high-risk women according to the risk classifications
featured in the report of clinical trials: three levels (X1.66, 3.01–
5.00%, X5.01%) of a 5-year predicted breast cancer risk, with a
history of lobular carcinoma in situ (LCIS), and with a history of
atypical hyperplasia (AH). A 5-year predicted breast cancer risk of
an individual woman used in the trials is based on Gail et al model
2 (Gail and Costantino, 2001), which is validated for white women
(Rockhill et al, 2001) and African American women (Gail et al,
2007), to date. We assume the same model is good for Japanese
women.
We also model the ages of starting prophylaxis: 35, 50, 60 years
old for tamoxifen, and 50, 60 years old for raloxifene taking the
menopause into account.
Markov model
We construct a Markov model of courses followed by high-risk
women, which is shown in Figure 1. Eight health states are
modelled according to clinical events monitored and found
significant in P-1 trial and P-2 trial: (1) healthy; (2) invasive
breast cancer; (3) noninvasive breast cancer, (4) endometrial
cancer; (5) pulmonary embolism; (6) cataract; (7) hip fracture; and
(8) dead. Healthy women at high risk of the disease, women with
invasive and noninvasive breast cancer are the target health states
for chemoprevention. An increase in risk of endometrial cancer,
pulmonary embolism, and cataract are known as adverse effects of
SERMs, whereas a decrease in risk of hip fracture is known as a
beneficial effect. Transitions between health states are indicated
with arrows.
The time span of each stage is set at 1 year, since trials report
annual incidence rates. Markov process is repeated until death or
age 100, whichever comes first, since all events are expected to
occur within this time horizon. Women who survive after the age
of 100 years are assumed to die regardless of breast cancer
development.
Chemoprevention
Prophylaxis with SERMs is continued for 5 years, or discontinued
in case of adverse events, which is similar to the regimen employed
in clinical trials.
Comparisons
We compare outcomes and costs in terms of incremental cost-
effectiveness ratios (ICERs) between status quo in Japan, without
prophylaxis, and hypothetical practise, with prophylaxis, by the
agent (tamoxifen and raloxifene), the risk classification, and the
age of starting prophylaxis.
ICER ¼
Costwithprophylaxis   Costwithoutprophylaxis
Effectwithprophylaxis   Effectwithoutprophylaxis
We also compare prophylaxis with tamoxifen and prophylaxis with
raloxifene to estimate the relative value of raloxifene to tamoxifen,
although this does not depict any marginal change in Japan.
Outcome estimation
Outcomes in terms of life years gained (LYGs) and quality adjusted
life years (QALYs) are estimated by assigning transitional
probabilities and utility weights to Markov model from the
literature.
Transitional probabilities from healthy state to disease states in
Markov model are shown in Table 1 according to the findings from
the clinical trials. Risk reduction effect of SERMs is assumed to
continue during the 5-year course of prophylaxis.
Table 2 summarises other assumptions such as transitional
probabilities from disease states to dead state and utility weights
used in Markov model. The share of clinical stages of invasive
breast cancer at diagnosis are adopted from a nationwide survey
on breast cancer screening (Japan Cancer Society, 2007), of which
prognosis is calculated from corresponding follow-up cases at
Tokyo Metropolitan Cancer and Infectious Disease Centre
Komagome Hospital. The prognosis of endometrial cancer is also
adopted from a nationwide cancer registry (Japanese Society of
Obstetrics and Gynecology, 2000). The prognosis of pulmonary
embolism and hip fracture are taken from Sakuma et al (2004);
Kitamura et al (1998), respectively. Japanese female population
High-risk women
healthy
Endometrial
cancer
Pulmonary
embolism
Noninvasive
breast cancer
Hip
fracture Cataract
Invasive
breast cancer
Dead
Figure 1 Markov model.
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smortality rates from Vital Statistics (Ministry of Health, Labour
and Welfare, 2005a) are applied for other transitions to dead state.
It is more preferable to adopt utility weights from a consistent
study that assesses our six disease states in Japan, but there is no
Japanese utility weight in the literature to date, which may be
applied to any health states in our model. To illustrate the typical
patient states, we adopt the weights assessed in developed
countries considering them as the best available knowledge, and
choosing them under the consensus of staff doctors at Tokyo
Metropolitan Cancer and Infectious Disease Centre Komagome
Hospital (de Koning et al, 1991; Hillner et al, 1993; Smith and
Hillner, 1993; Grann et al, 1998; Earle et al, 2000; Armstrong et al,
2001; Chau et al, 2003; Cykert et al, 2004; Naeim and Keeler, 2005;
Ruof et al, 2005).
Outcome is discounted at a rate of 3%.
Costing
From societal perspective, costing should cover the opportunity
cost borne by various economic entities in the society. In the
context of this study, costs borne by women or third party payers
including the government and social insurers are considered,
although there is no particular assumption about who bears the
cost of chemoprevention. According to the national medical care
fee schedule, the amount of direct payments to health-care
providers is estimated as cost, whereas costs to sectors other than
health and productivity losses are left uncounted.
Health states are identified as cost items in Markov model.
Table 3 summarises the cost of each health states. Being in healthy
state, women with chemoprevention take 20mg per day, f82.6
(d0.41; d1¼f200), of tamoxifen, or 60mg per day, f148.5 (d0.74),
of raloxifene, prescribed regularly for 5 years, and annual
mammography checkup. Women without chemoprevention also
undergo annual mammography checkup. Although the state is
labelled as ‘healthy’, it includes all other diseases that are not
modelled in Markov model. Annual treatment costs by the age
stratum are approximated by annual health-care expenditure per
woman adopted from National Health-Care Expenditure (Ministry
of Health, Labour and Welfare, 2005b). As it is well known that the
cost of health care in the last year of life tends to be large, these are
shown separately after an adjustment based on Fukawa (1998).
Table 3 also summarises the treatment cost of invasive breast
cancer by the age stratum. In the case of cancer care, the cost in the
first year after diagnosis tends to be large as well as in the last year
of life, so here again, the costs are shown separately. These figures
are obtained from insurance claim reviews at Tokyo Metropolitan
Cancer and Infectious Disease Centre Komagome Hospital. As to
the cost of the first year, recent breast cancer cases of stage I and
Table 1 Transitional probabilities from healthy state to disease states in Markov model
Placebo Tamoxifen Raloxifene
Base-case
value Source
Base-case
value
Range tested in
sensitivity
analysis
a Source
Base-case
value
Range tested in
sensitivity
analysis
a Source
Invasive breast cancer
Five-year predicted breast cancer risk X1.66%
Age of starting prophylaxis
35 0.00632 Fisher et al (2005) 0.00404 0.00235–0.00641 Fisher et al (2005)
50 0.00587 Fisher et al (2005) 0.00333 0.00168–0.00573 Fisher et al (2005) 0.00310 0.00184–0.00490 Fisher et al (2005),
Vogel et al (2006)
60 0.00668 Fisher et al (2005) 0.00330 0.00165–0.00567 Fisher et al (2005) 0.00366 0.00213–0.00585 Fisher et al (2005),
Vogel et al (2006)
Five-year predicted
breast cancer risk
3.01–5.00%
0.00451 Fisher et al (2005) 0.00270 0.00108–0.00534 Fisher et al (2005) 0.00203 0.00101–0.00349 Fisher et al (2005),
Vogel et al (2006)
Five-year predicted
breast cancer risk
X5.01%
0.01198 Fisher et al (2005) 0.00515 0.00245–0.00893 Fisher et al (2005) 0.00561 0.00323–0.00894 Fisher et al (2005),
Vogel et al (2006)
History of lobular
carcinoma in situ
0.01170 Fisher et al (2005) 0.00627 0.00161–0.01476 Fisher et al (2005) 0.00614 0.00239–0.01226 Fisher et al (2005),
Vogel et al (2006)
History of atypical
hyperplasia
0.01042 Fisher et al (2005) 0.00255 0.00029–0.00686 Fisher et al (2005) 0.00286 0.00133–0.00523 Fisher et al (2005),
Vogel et al (2006)
Noninvasive breast
cancer
0.00012 Fisher et al (2005) 0.00004 0.00000–0.00652 Fisher et al (2005) 0.00006 0.00003–0.00009 Fisher et al (2005,
Vogel et al (2006)
Endometrial cancer
Age of starting prophylaxis
35 0.00082 Fisher et al (2005) 0.00116 0.00010–0.00410 Fisher et al (2005)
50 and 60 0.00058 Fisher et al (2005) 0.00308 0.00061–0.00992 Fisher et al (2005) 0.00194 0.00065–0.00403 Fisher et al (2005),
Vogel et al (2006)
Pulmonary embolism
Age of starting prophylaxis
35 0.00013 Fisher et al (2005) 0.00025 0.00000–0.00420 Fisher et al (2005)
50 and 60 0.00044 Fisher et al (2005) 0.00096 0.00020–0.00275 Fisher et al (2005) 0.00061 0.00028–0.00114 Fisher et al (2005),
Vogel et al (2006)
Cataract 0.02285 Fisher et al (2005) 0.02775 0.02384–0.03206 Fisher et al (2005) 0.02192 0.01735–0.02734 Fisher et al (2005),
Vogel et al (2006)
Hip fracture 0.00086 Fisher et al (2005) 0.00059 0.00022–0.00122 Fisher et al (2005) 0.00052 0.00016–0.00115 Fisher et al (2005),
Vogel et al (2006)
a1.5 times of 95% confidence interval.
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sstage II that have undergone initial treatment with a follow-up of 1
year are retrospectively selected so that each age strata has 40
cases. As to the yearly cost of the second year and thereafter, 40
cases for each age strata are randomly selected from follow-up
cases initially diagnosed as stage I and stage II. As to the cost of the
last year of life, recent 80 fatal cases are retrospectively selected, as
the number of these is relatively limited. Insurance claims of these
total of 400 cases for 1 year are reviewed to calculate average
annual costs by the age strata. Then an adjustment is made to
include the cost of prescription to be filled at external pharmacies,
such as in the case of adjuvant hormonal therapy, which is based
on the consensus among staff doctors.
Costs of disease states are summarised in Table 3 as well.
Treatment costs of noninvasive breast cancer, endometrial cancer,
cataract, and hip fractures are adopted from a background study
for the development of Japanese prospective payment system to
health-care providers, diagnosis procedure combination (Matsuda
and Ishikawa, 2003), whereas treatment cost of pulmonary
embolism is adopted from Fuji et al (2005).
Costs are also discounted at a rate of 3%.
Sensitivity analyses
To deal with the uncertainty of probabilities, utility weights, and
costs used in our economic model, one-way sensitivity analyses are
performed. Transitional probabilities from healthy state to disease
states shown in Table 1 are varied in 1.5 times of 95% confidence
intervals (CI) reported from the clinical trials. 95% CI is often used
for similar exercises of sensitivity analyses, but we set wider range
for the applicability of the clinical trial data to Japanese women.
The other probabilities shown in Table 2 are changed by ±50%.
Utility weights are changed by ±20%, and we think this could
cover the difference between the utility weights of Japanese women
and those of the other developed nations. Costs shown in Table 3
are changed by ±50%. Discount rate is also changed from 0 to 6%.
Acknowledging the long-term outcomes for tamoxifen in the
IBIS-I trial (Cuzick et al, 2007) and the Royal Marsden trial
(Powles et al, 2007), risk reduction effect of tamoxifen is prolonged
from 5 to 10 and 15 years without any risk increase of adverse
events after the completion of prophylaxis.
RESULTS
Outcomes
Table 4 shows the results of cost-effectiveness analysis comparing
prophylaxis with no prophylaxis.
In the comparison between prophylaxis with tamoxifen vs no
prophylaxis, most outcomes in terms of LYGs are increased by
chemoprevention except for women with a 5-year predicted breast
cancer risk of X1.66% starting at age 50, and women with a 5-year
predicted breast cancer risk of 3.01–5.00% starting at age 50 and
60. Outcomes in terms of QALYs are also increased except for
women with a 5-year predicted breast cancer risk of X1.66%
starting at age 50 and 60, women with a 5-year predicted breast
cancer risk of 3.01–5.00%, and women with a history of LCIS
starting at age 60. The largest outcome gain in terms of QALYs,
0.105, is estimated among women with a history of AH starting at
age 35.
Between prophylaxis with raloxifene vs no prophylaxis, all
outcomes in terms of LYGs are increased by chemoprevention.
Outcomes in terms of QALYs are increased except for women with
a 5-year predicted breast cancer risk of X1.66%, and women with
Table 2 Assumptions used in Markov model
Assumption
Range tested
in sensitivity
analysis Source
Transitional probabilities from disease states to dead state
Invasive breast cancer 0–9 years after diagnosis: prognosis of Japanese breast
cancer patients by the stage
Change by±50% Calculated from follow-up patients at Komagome
Hospital
Stage I: 0.0074, 0.0155, 0.0113, 0.0218, 0.0254,
0.0248, 0.0289, 0.0165, 0.01632
Stage II: 0.0054, 0.0474, 0.0570, 0.0334, 0.0398,
0.0321, 0.0275, 0.0295, 0.04672
(Proportions of stage at diagnosis are assumed
stage I as 72% and stage II as 28%)
Change by±50% Japan Cancer Society (2007)
Thereafter: Japanese female population mortality rates Change by±50% Ministry of Health, Labour and Welfare (2005a)
Noninvasive breast cancer Japanese female population mortality rates Change by±50% Ministry of Health, Labour and Welfare (2005a)
Endometrial cancer 0–4 years after diagnosis: prognosis of Japanese
endometrial cancer patients 0.0660, 0.0546, 0.0328,
0.02813
Change by±50% Japanese Society of Obstetrics and Gynecology (2000)
Thereafter: Japanese female population mortality rates Change by±50% Ministry of Health, Labour and Welfare (2005a)
Pulmonary embolism 0 year after diagnosis: 0.08 Change by±50% Sakuma et al (2004)
Thereafter: Japanese female population mortality rates Change by±50% Ministry of Health, Labour and Welfare (2005a)
Cataracts Japanese female population mortality rates Change by±50% Ministry of Health, Labour and Welfare (2005a)
Hip fracture 0–1 years after diagnosis: 0.11 and 0.19, respectively Change by±50% Kitamura et al (1998)
Thereafter: Japanese female population mortality rates Change by±50% Ministry of Health, Labour and Welfare (2005a)
Utility weights
Healthy 1.00 Change by±20%
Healthy under
chemoprevention for 5 years
0.99 Change by±20% Smith and Hillner (1993), Hillner et al (1993),
Naeim and Keeler (2005)
Invasive breast caner 0 year after diagnosis: 0.87, thereafter: 0.89 Change by±20% de Koning et al (1991), Grann et al (1998)
Noninvasive breast cancer 0.98 Change by±20% Earle et al (2000)
Endometrial cancer 0 year after diagnosis: 0.83, thereafter: 0.88 Change by±20% Armstrong et al (2001), Cykert et al (2004)
Pulmonary embolism 0.70 Change by±20% Chau et al (2003)
Cataract surgery 0.96 Change by±20% Ruof et al (2005)
Hip fracture 0–1 years after diagnosis: 0.61 and 0.92, respectively Change by±20% Armstrong et al (2001)
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sTable 3 Costs (f)
Healthy Breast cancer
Base-case
value
Range tested in
sensitivity
analysis Source
Base-case
value
Range tested
in sensitivity
analysis Source
Chemoprevention
Tamoxifen 30149 Change by±50% Drug price list, etc
Raloxifene 54203 Change by±50%
Prescription+annual
mammography
44980 Change by±50%
Annual mammography 15520 Change by±50%
Ages 35–49
First year after diagnosis 1978064 Change by±50%
Yearly cost 383743 Change by±50%
Ages 35–39 81937 Change by±50%
Ages 40–44 94529 Change by±50% Ministry of Health,
Labour and Welfare
(2005b), Fukawa
(1998)
Insurance
claim
review
Ages 45–49 110604 Change by±50%
Terminal care cost, last year of life 5495224 Change by±50%
Ages 35–39 352331 Change by±50%
Ages 40–44 406474 Change by±50%
Ages 45–49 475599 Change by±50% Change by±50%
Ages 50–64
First year after diagnosis 2211083 Change by±50%
Yearly cost 542857 Change by±50%
Ages 50–54 151625 Change by±50% Ministry of Health,
Labour and Welfare
(2005b), Fukawa
(1998)
Insurance
claim
review
Ages 55–59 195085 Change by±50%
Ages 60–64 258723 Change by±50%
Terminal care cost, last year of life 4106271 Change by±50%
Ages 50–54 651986 Change by±50%
Ages 55–59 838866 Change by±50%
Ages 60–64 1112510 Change by±50%
Ages 65–79
First year after diagnosis 1530259 Change by±50%
Yearly cost 441458 Change by±50%
Ages 65–69 324347 Change by±50%
Ages 70–74 460617 Change by±50% Ministry of Health,
Labour and Welfare
(2005b), Fukawa
(1998)
Insurance
claim
review
Ages 75–79 549284 Change by±50%
Terminal care cost, last year of life 3252302 Change by±50%
Ages 65–69 1394690 Change by±50%
Ages 70–74 1980653 Change by±50%
Ages 75–79 2361923 Change by±50%
Ages 80+
First year after diagnosis Ministry of Health,
Labour and Welfare
(2005b), Fukawa
(1998)
961181 Change by±50% Insurance
claim
review
Yearly cost 185151 Change by±50%
Ages 80–84 576290 Change by±50%
Ages 85–89 647941 Change by±50%
Ages 90–94 557429 Change by±50%
Ages 95–100 465059 Change by±50%
Terminal care cost, last year of life 427042 Change by±50%
Ages 80–84 2478049 Change by±50%
Ages 85–89 2786147 Change by±50%
Ages 90–94 2396943 Change by±50%
Ages 95–100 1999754 Change by±50%
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sa 5-year predicted breast cancer risk of 3.01–5.00%. The largest
outcome gain in terms of QALYs, 0.058, is estimated among
women with a history of AH starting at age 50.
Table 5 shows the results of cost-effectiveness analysis of
therapeutic policy switch from tamoxifen to raloxifene.
Raloxifene is consistently superior to tamoxifen across
presented risk classifications and starting ages of prophylaxis.
Costs
In the comparison between prophylaxis with tamoxifen vs no
prophylaxis (Table 4), cost savings are estimated in higher risk
classifications, among women with a history of LCIS or AH,
starting at younger age. The largest saving, f367901 (d1840), is
estimated among women with a history of AH starting at age 35.
Between prophylaxis with raloxifene vs no prophylaxis, prophy-
laxes are found more costly. A cost saving of f10387 (d52) is
estimated among women with a history of AH starting at age 50.
When considering the therapeutic policy switch (Table 5), the
use of raloxifene is consistently more costly than tamoxifen, as
anticipated by the difference in price of agents.
Cost-effectiveness
There is a suggested criterion for cost-effectiveness in Japan
(Ohkusa, 2003) to be f6000000 (d30000) for one QALY gain, and
both Tables 4 and 5 report judgements with this criterion.
In the comparison between prophylaxis with tamoxifen vs no
prophylaxis, favourable results, that is ‘cost less and gain more’ or
cost-effective, are obtained in higher risk classifications starting at
younger age. Those are: women with a history of AH regardless of
starting age, women with a history of LCIS starting at age 35 and
50, and women with a 5-year predicted breast cancer risk of
X5.01% starting at age 35 and 50.
Similar results are found between prophylaxis with raloxifene
vs no prophylaxis. Favourable results are: women with a history of
AH regardless of starting age, women with a history of LCIS
starting at age 50, and women with a 5-year predicted breast cancer
risk of X5.01% starting at age 50.
As shown in Table 5, ICERs for the therapeutic policy switch of
prophylactic agent from tamoxifen to raloxifene varies from
f1839670 per QALY (d9198 per QALY) to f6771100 per QALY
(d33856 per QALY). The larger ICER is yet still close to the
suggested criterion of f6000000 per QALY (d30000 per QALY).
Stability of cost-effectiveness
One-way sensitivity analyses produce similar results across the
agents, the risk classifications and the ages of starting prophylaxis.
Therefore, we draw a cost-effectiveness plane to show the
comparison between prophylaxis with raloxifene vs no prophylaxis
among three risk classifications as an example: women with a
5-year predicted breast cancer risk of X5.01%, women with a
history of LCIS, and women with a history of AH.
Figure 2 plots three base-case values and 306 results (102
changes of variables three different risk classifications). Line OA
indicates the threshold of favourable ICER compared to the
suggested criterion of f6000000 (d30000) for one QALY gain.
Most results are plotted close to base-case value, which suggest the
stability of our model. Results for women with a history of AH
remain constantly favourable being cost saving or cost-effective by
the change of variables except for one plot shown as in area B.
However, several results for women with a 5-year predicted breast
cancer risk of X5.01% and for women with a history of LCIS cross
the threshold line, the vertical axis or the horizontal axis from the
base-case values. Three plots in area B and seven plots in area C
indicate that results turn unfavourably, that is cost-ineffective or
‘gain less’, whereas plots in area D show that results become cost
saving.
Our model is most sensitive to the utility weight for healthy
state under chemoprevention, of which plots are drawn in area B.
Its change to 0.79 turns incremental effectiveness into
Table 3 (Continued)
Diseases
Base-case value Range tested in
sensitivity analysis
Source
Noninvasive breast cancer surgery, etc
(DPC0900103x020xxx+
reimbursements by FFS)
847928 Change by±50% Matsuda and Ishikawa
(2003)
Endometrial cancer
Total hysterectomy, etc
(DPC 1200203x01x0xx+
reimbursements by FFS)
1183839 Change by±50% Matsuda and Ishikawa
(2003)
Pulmonary embolism
Total 469890
(Diagnosis) (52350) Change by±50% Fuji et al (2005)
(Treatment) (417540)
Cataract
Surgery, etc (DPC 0201103x01x
000+reimbursements by FFS)
309120 Change by±50% Matsuda and Ishikawa
(2003)
Hip fracture
Surgery, etc (DPC
1608003x02xx0x+
reimbursements by FFS)
1553195 Change by±50% Matsuda and Ishikawa
(2003)
DPC: diagnosis procedure combination; FFS: fee for service.
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snegative. Critical values to change the judgement are 0.98, which
makes the ICERs of women with a 5-year predicted breast
cancer risk of X5.01% and woman with a history of LCIS
cost-ineffective, and the value of 0.96 makes women with a
history of AH ‘gain less’. The model is also sensitive to the
discount rate, of which plot is drawn in area C. Its raise of 5.9
and 4.3% makes the ICERs of women with a 5-year predicted
breast cancer risk of X5.01% and women with a history of
Table 4 Results of cost-effectiveness analysis (1)
CoCost (f) Effectiveness (LYGs) Effectiveness (QALYs)
Incremental cost-
effectiveness ratio
No prophylaxis vs
prophylaxis
with tamoxifen
No
prophylaxis Tamoxifen Incremental
No
prophylaxis Tamoxifen Incremental
No
prophylaxis Tamoxifen Incremental (f/LYG) (f/QALY)
Five-year predicted breast cancer risk X1.66%
Starting at age 35 13958679 13983626 24947 25.916 25.953 0.037 25.757 25.759 0.002 678210 14247447
Starting at age 50 17630814 17751353 120538 22.168 22.167  0.001 22.040 22.000  0.040 Cost more,
gain less
Cost more,
gain less
Starting at age 60 20160906 20324294 163388 18.806 18.807 0.001 18.688 18.654  0.034 120849008 Cost more,
gain less
Five-year predicted breast cancer risk 3.01–5.00%
Starting at age 35 13627472 13685368 57896 26.005 26.035 0.030 25.879 25.872  0.007 1946092 Cost more,
gain less
Starting at age 50 17579407 17732900 153493 22.195 22.185  0.010 22.088 22.037  0.051 Cost more,
gain less
Cost more,
gain less
Starting at age 60 20251937 20444141 192203 18.808 18.797  0.011 18.718 18.666  0.052 Cost more,
gain less
Cost more,
gain less
Five-year predicted breast cancer risk X5.01%
Starting at age 35 14956349 14667969  288380 25.651 25.755 0.105 25.396 25.480 0.084 Cost less,
gain more
Cost less,
gain more
Starting at age 50 17867146 17800766  66379 22.049 22.096 0.047 21.832 21.854 0.022 Cost less,
gain more
Cost less,
gain more
Starting at age 60 19958433 20058020 99857 18.797 18.825 0.028 18.614 18.618 0.004 3548049 26648821
History of lobular carcinoma in situ
Starting at age 35 14908314 14717649  190665 25.663 25.747 0.083 25.414 25.472 0.058 Cost less,
gain more
Cost less,
gain more
Starting at age 50 17856158 17850722  5386 22.054 22.085 0.031 21.841 21.843 0.002 Cost less,
gain more
Cost less,
gain more
Starting at age 60 19968466 20093211 124745 18.798 18.815 0.017 18.618 18.606  0.011 7282700 Cost more,
gain less
History of atypical hyperplasia
Starting at age 35 14687003 14319102  367901 25.722 25.844 0.122 25.493 25.598 0.105 Cost less,
gain more
Cost less,
gain more
Starting at age 50 17806095 17692020  114075 22.079 22.139 0.060 21.884 21.922 0.038 Cost less,
gain more
Cost less,
gain more
Starting at age 60 20015243 20096731 81488 18.800 18.837 0.037 18.635 18.651 0.016 2226684 5234647
a
No prophylaxis vs
prophylaxis with
raloxifene
No
prophylaxis Raloxifene Incremental
No
prophylaxis Raloxifene Incremental
No
prophylaxis Raloxifene Incremental (f/LYG) (f/QALY)
Five-year predicted breast cancer risk X1.66%
Starting at age 50 17630814 17833020 202206 22.168 22.190 0.022 22.040 22.027  0.013 9256382 Cost more,
gain less
Starting at age 60 20160906 20427386 266480 18.806 18.822 0.016 18.688 18.670  0.018 16806286 Cost more,
gain less
Five-year predicted breast cancer risk 3.01–5.00%
Starting at age 50 17579407 17794890 215482 22.195 22.214 0.019 22.088 22.071  0.017 11599422 Cost more,
gain less
Starting at age 60 20251937 20529452 277515 18.808 18.820 0.012 18.718 18.694  0.024 23845594 Cost more,
gain less
Five-year predicted breast cancer risk X5.01%
Starting at age 50 17867146 17911198 44053 22.049 22.111 0.062 21.832 21.871 0.039 705126 1123880
a
Starting at age 60 19958433 20161888 203455 18.797 18.839 0.042 18.614 18.633 0.019 4848677 10664954
History of lobular carcinoma in situ
Starting at age 50 17856158 17935697 79540 22.054 22.107 0.053 21.841 21.869 0.027 1496425 2904386
a
Starting at age 60 19968466 20186549 218083 18.798 18.833 0.036 18.618 18.628 0.010 6133167 21462765
History of atypical hyperplasia
Starting at age 50 17806095 17795708  10387 22.079 22.156 0.077 21.884 21.942 0.058 Cost less,
gain more
Cost less,
gain more
Starting at age 60 20015243 20198328 183085 18.800 18.852 0.052 18.635 18.668 0.033 3527453 5570154
a
aCost-effective when compared to a suggested criterion in Japan (Ohkusa, 2003) of f6000 000 for one QALY gain.
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sLCIS cost-ineffective, respectively. The cost of chemoprevention is
also influential to the results, of which results are shown in
areas C and D. A price increase of more than 30% for raloxifene
makes the ICER of women with a history of LCIS cost-ineffective,
whereas a price decrease of more than 16 or 29% make the
results for women with a 5-year predicted breast cancer risk of
X5.01% and women with a history of LCIS cost saving,
respectively. Changes of the probabilities of transition to invasive
breast cancer, endometrial cancer, and hip fracture are also plotted
in areas C and D. Raising the probability of invasive breast cancer
beyond 0.00710 and 0.00683 makes the ICERs of women with a
5-year predicted breast cancer risk of X5.01% and women with a
history of LCIS cost-ineffective, whereas lowering to less than
0.00456 or 0.00436 make the results for women with a 5-year
predicted breast cancer risk of X5.01% and women a history of
LCIS cost saving, respectively. Raising the probability of endo-
metrial cancer beyond 0.00369 and 0.00271 makes the ICERs of
women with a 5-year predicted breast cancer risk of X5.01% and
women with a history of LCIS cost-ineffective, respectively. Raising
probability of hip fracture beyond 0.00098 makes the results for
women with a history of LCIS cost saving. The other plots in area C
reflect a raise of utility weight for invasive breast cancer after the
second year.
Prolonging risk reduction effect of tamoxifen from 5 to 10
and 15 years without any risk increase of adverse events
after the completion of prophylaxis brings more favourable
results. For example, the effect of 10 years results in ‘cost
less and gain more’ for every risk classification starting at
age 35, whereas the effect of 15 years makes no change in the
results of ‘cost more and gain less’ among women with a
5-year predicted breast cancer risk of X1.66% starting at age
50 and 60.
Table 5 Results of cost-effectiveness analysis (2)
Cost (f) Effectiveness (LYGs) Effectiveness (QALYs)
Incremental
cost-effectiveness
ratio
Prophylaxis with
tamoxifen vs
prophylaxis with
raloxifene Tamoxifen Raloxifene Incremental Tamoxifen Raloxifene Incremental Tamoxifen Raloxifene Incremental (f/LYG) (f/QALY)
Five-year predicted breast cancer risk X1.66%
Starting at age 50 17751353 17833020 81667 22.167 22.190 0.023 22.000 22.027 0.027 3501723 3035955
a
Starting at age 60 20324294 20427386 103093 18.807 18.822 0.015 18.654 18.670 0.016 7107875 6364920
Five-year predicted breast cancer risk 3.01–5.00%
Starting at age 50 17732900 17794890 61990 22.185 22.214 0.029 22.037 22.071 0.034 2163079 1839670
a
Starting at age 60 20444141 20529452 85312 18.797 18.820 0.023 18.666 18.694 0.028 3741906 3063477
a
Five-year predicted breast cancer risk X5.01%
Starting at age 50 17800766 17911198 110432 22.096 22.111 0.015 21.854 21.871 0.017 7150490 6542190
Starting at age 60 20058020 20161888 103869 18.825 18.839 0.014 18.618 18.633 0.015 7476332 6771100
History of lobular carcinoma in situ
Starting at age 50 17850772 17935697 84925 22.085 22.107 0.022 21.843 21.869 0.025 3846426 3359650
a
Starting at age 60 20093211 20186549 93338 18.815 18.833 0.018 18.606 18.628 0.022 5064724 4311015
a
History of atypical hyperplasia
Starting at age 50 17692020 17795708 103688 22.139 22.156 0.018 21.922 21.942 0.019 5922294 5320037
a
Starting at age 60 20096731 20198328 101598 18.837 18.852 0.015 18.651 18.668 0.017 6637332 5872017
a
aCost-effective when compared to a suggested criterion in Japan (Ohkusa, 2003) of f6000000 for one QALY gain.
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Figure 2 Illustration of key results of sensitivity analyses: prophylaxis with raloxifene vs no prophylaxis starting at age 50.
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sDISCUSSION
We conduct a cost-effectiveness analysis of SERMs as prophylactic
agents against breast cancer among high-risk women by making
comparisons between status quo in Japan, without prophylaxis,
and hypothetical practise, with prophylaxis, by the agent
(tamoxifen and raloxifene), the risk classification, and the age of
starting prophylaxis.
We find that prophylaxis with tamoxifen results in ‘cost less
and gain more’ among extremely high-risk women such as
those with a 5-year predicted breast cancer risk of X5.01%, those
with a history of LCIS, and those with a history of AH starting
at age 35 and 50. Prophylaxis with raloxifene is also found
‘cost less and gain more’ for women with a history of AH
starting at age 50. The younger the age of starting prophylaxis, the
more the cost saving and outcome gain. We also find that
prophylaxis with tamoxifen for women with a history of AH
starting at age 60 results in favourable ICER compared to the
suggested criterion of f6000000 (d30000) for one QALY gain.
Prophylaxis with raloxifene is also found cost-effective for
women with a 5-year predicted breast cancer risk of X5.01%
starting at age 50, those with a history of LCIS starting at
age 50 and those with a history of AH starting at age 60.
The younger the age of starting prophylaxis, the more
favourable the ICER. Within the same risk classification and
starting age, raloxifene tends to gain more and cost more
compared to tamoxifen. On the contrary, we also find that
prophylaxes with tamoxifen or raloxifene for women with a 5-year
predicted breast cancer risk of p5.00% tend to result in ‘cost more
and gain less’.
These findings are similar to the previous economic
evaluations of chemoprevention of breast cancer with
tamoxifen including analyses of risk level differences such as
Noe et al (1999); Grann et al (2000); Hershman et al (2002);
Melnikow et al (2006), although these studies are carried out
under the US health system.
Our findings suggest that introduction of chemoprevention with
SERMs targeting extremely high-risk women in Japan can be
justifiable as an efficient use of finite health-care resources,
possibly contributing to cost containment. The cost saving results
suggest chemoprevention not only cost-effective but also afford-
able. Taking the superiority of raloxifene in outcome gain and the
difference in indication into account, it is recommendable to
administer tamoxifen for premenopausal women and raloxifene
for postmenopausal women.
Our economic model is found sensitive to the utility weight for
healthy state under chemoprevention, the discount rate and the
cost of chemoprevention, in addition to the probabilities of
transition to invasive breast cancer, endometrial cancer, or hip
fracture. This is anticipated because these variables are supposed
to influence the cost-effectiveness of preventive services. We think
that our economic model succeeds in explaining the context under
consideration.
We also analysed the cost-effectiveness of therapeutic policy
switch of agent, tamoxifen to raloxifene among postmenopausal
women, although this does not depict any marginal change in
Japan. All simulated ICERs by risk classifications starting at age 50
and 60 fall in a favourable level. Due caution is needed in
transferring these findings from our Japanese model to other
health system (Drummond and Pang, 2001), but it implies that the
administration of raloxifene instead of tamoxifen for postmeno-
pausal high-risk women could be economically acceptable in
developed countries where chemoprevention with tamoxifen is
already in practise.
There are a couple of points to consider when interpreting
our results. Our model depends on clinical evidence established in
the United States by P-1 and P-2 trial. Composition of ethnicity
and life styles of participating women are different from
those of Japanese women. This also relates to another point, that
is the validity of the 5-year risk prediction model defining high-
risk women. As already mentioned in Methods section, it is based
on Gail et al model 2 (Gail and Costantino, 2001), which has
been validated for white women (Rockhill et al, 2001) and African
American women (Gail et al, 2007) only. Our approach is
acceptable as to these points, as the results of P-1 and P-2 trial
are the best available evidence to date for the objectives of this
study, and similar risk factors to Gail et al model 2 are identified in
a model of individualised probability of developing breast cancer
for Japanese women (Ueda et al, 2003), and the function of ethnic
difference in developing breast cancer is reported as small (Chen
et al, 2004). Our model also depends on utility weights reported
from Western countries, as none of those from Japan are available.
However, our findings of consistent outcomes in terms of LYGs
offer reasonable conclusions.
In summary, this study suggests that chemoprevention of breast
cancer with SERMs targeting high-risk women such as a 5-year
predicted breast cancer risk of X5.01%, women with a history of
LCIS, and women with a history of AH, clears the hurdles of
introducing new intervention by means of cost-effectiveness and
affordability, with best available evidence. Although further studies
and policy formulations are necessary about breast cancer
chemoprevention in Japan, this study also implies that the
administration of raloxifene instead of tamoxifen may be cost-
effective under the context of developed countries where
chemoprevention with tamoxifen has already been adopted.
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